Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
Strata Skin Sciences Inc (SSKN) provides innovative medical technologies for dermatology practices, specializing in excimer laser treatments for conditions like psoriasis and vitiligo. This news hub offers investors and healthcare professionals timely updates on SSKN's financial developments, product innovations, and strategic partnerships.
Access official press releases covering quarterly earnings, FDA clearances, clinical study results, and partnership expansions with dermatology clinics. Our curated collection simplifies tracking SSKN's progress in advancing in-office phototherapy solutions and its unique recurring revenue model.
Discover updates about the XTRAC® excimer laser system, VTRAC™ lamp technologies, and SSKN's practice support programs. Content is organized chronologically for quick reference, with clear sourcing for regulatory filings and corporate announcements.
Bookmark this page to stay informed about SSKN's position in the $12B+ global dermatology devices market. Verify all information directly with SEC filings or company communications before making financial decisions.
STRATA Skin Sciences (NASDAQ: SSKN) announced that a poster detailing the efficacy of its TheraClearX acne system was accepted for presentation at the ODAC Dermatology Conference from January 12-15, 2023. The study involved 10 patients with mild to moderate acne who underwent tailored photopneumatic therapy (PPT). All participants experienced visible reductions in acne lesions, with improvements noted in skin texture and pore size. Most responded positively after 2-3 sessions, showcasing the system's efficacy and safety. The findings reinforce STRATA's commitment to advancing treatment options for acne.
STRATA Skin Sciences (NASDAQ: SSKN) has entered an exclusive agreement with MINO Labs to distribute its dermatological products in Mexico for three years. This partnership aims to tap into a nearly $300 million market for treating acne, psoriasis, and vitiligo, addressing a significant need as 80% of the Mexican population suffers from acne. MINO Labs brings over 20 years of experience in the pharmaceutical sector, ensuring effective distribution through established sales channels. This collaboration is expected to expand treatment options for patients in Mexico.
HORSHAM, Pa., Dec. 02, 2022 – STRATA Skin Sciences, a medical technology company focused on dermatologic treatments, announced its presentation at the Cantor Medical & Aesthetic Dermatology Conference on December 8, 2022, at 1:45 PM EST. The session, titled Aesthetically Pleasing & Medically Necessary, will explore leading devices in the field. STRATA Skin Sciences specializes in innovative products for conditions like psoriasis and acne, offering solutions like XTRAC® and TheraClear® systems via a unique partnership program.
STRATA Skin Sciences reported strong Q3 2022 financial results, achieving revenues of $9.4 million, a 22% increase from Q3 2021. International sales soared to $3.3 million, marking an 82% rise year-over-year. The company launched the TheraClear®X acne therapy system, positioning itself in the $5.5 billion acne treatment market. Despite this growth, gross profit fell to 61.6% of revenues, down from 69.7% in the same quarter last year. STRATA reiterated its 2022 revenue guidance of $33 million to $35 million.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology firm focused on dermatologic treatments, will release its Q3 2022 financial results on November 9, 2022. A conference call will follow at 4:30 PM EST to discuss the results and provide updates. The company offers innovative products such as the XTRAC® and Pharos® excimer lasers and the TheraClear® X Acne Therapy System, utilizing a unique partnership program that streamlines treatment accessibility for dermatologists.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced its participation in two upcoming investor events: the Microcap Rodeo: Windy City Roundup 2022 on October 12, 2022, and the LD Micro Main Event XV on October 26, 2022. At these events, the company will showcase its innovative dermatology products, including the XTRAC® and TheraClear® systems, which target conditions like psoriasis, acne, and vitiligo, impacting over 31 million patients in the U.S. STRATA employs a unique Direct to Consumer advertising model to boost awareness and patient volume for its partner dermatology clinics.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 3:30 PM ET. The event will be virtual, and management will present innovative advancements in dermatologic treatment technologies. Interested individuals can access the presentation via a live webcast through a provided link, with an archived version available on the company’s website post-event. STRATA focuses on developing treatments for conditions such as psoriasis and acne, impacting millions across the U.S.
STRATA Skin Sciences (NASDAQ: SSKN) reported second-quarter 2022 revenues of $9.1 million, a 23% increase from the previous year. Global recurring revenues remained stable at $5.6 million. The company launched TheraClear®X targeting the $5.5 billion acne care market. However, gross profit decreased to $5.0 million (55% margin) from $4.8 million (65% margin) due to higher amortization costs. A net loss of $1.9 million was recorded, compared to a net income of $1.1 million in Q2 2021. For 2022, STRATA anticipates revenue of $33.0 million to $35.0 million, indicating 10% to 17% growth.
STRATA Skin Sciences (NASDAQ: SSKN) announced the upcoming Key Opinion Leader (KOL) Call hosted by Ladenburg Thalmann on August 16, 2022, at 11:00 AM ET. Dr. Benjamin Lockshin will discuss the growing markets for psoriasis and vitiligo, emphasizing the role of STRATA’s XTRAC Excimer Laser in treatment outcomes. The call aims to highlight the company's innovative technologies, which include the XTRAC and Pharos excimer lasers and TheraClear X Acne Therapy System. Registration details for the live call are available on STRATA's website.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced plans to release its second quarter 2022 financial results on August 10, 2022, at 4:30 p.m. ET. The company will host a conference call to discuss these results and provide a corporate update, which will be available via webcast. STRATA specializes in developing and marketing innovative medical technologies for dermatologic conditions, including psoriasis and acne. Their offerings include excimer lasers and the new TheraClear®X Acne Therapy System.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
